Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

589
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
589
Drug Regulation01:25

Drug Regulation

3.1K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.1K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.3K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.3K
Drug Classes and Categories01:25

Drug Classes and Categories

3.2K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.2K
Drug Dependence01:17

Drug Dependence

1.8K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient and caregiver perspectives on transition from pediatric to adult care in inborn errors of immunity: a Polish multicenter survey.

Frontiers in immunology·2026
Same author

European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives.

Clinical and translational science·2026
Same author

Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months.

International journal of molecular sciences·2026
Same author

Non-classical immune checkpoint CD137/CD137L and CD200/CD200R expressions are regulated by the tumor immune microenvironment in lymph node aspirates from lung cancer patients.

Frontiers in immunology·2026
Same author

Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization.

Frontiers in immunology·2026
Same author

Analysis of financing of drug programs in allergology in 2020-2024.

Postepy dermatologii i alergologii·2026

Related Experiment Video

Updated: Feb 20, 2026

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
06:06

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

26.8K

Drug Policy in Poland.

Karina Jahnz-Różyk1, Pawel Kawalec2, Krzysztof Malinowski3

  • 1Department of Internal Medicine, Pneumonology, Allergology & Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine in Warsaw, Warsaw, Poland; ISPOR CEE Network Research, Education, Publication Committee.

Value in Health Regional Issues
|October 28, 2017
PubMed
Summary

Poland

Keywords:
Polandhealth care systempharmaceutical systempricingreimbursement

More Related Videos

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm
08:29

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm

Published on: June 7, 2018

12.3K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.4K

Related Experiment Videos

Last Updated: Feb 20, 2026

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
06:06

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

26.8K
Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm
08:29

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm

Published on: June 7, 2018

12.3K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.4K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Systems

Background:

  • Poland's healthcare system strives for accessible, safe, and effective medicines.
  • Patient co-payment for pharmacotherapy remains high, exceeding 60% despite policy goals.
  • The Ministry of Health oversees pricing and reimbursement, supported by specialized agencies.

Purpose of the Study:

  • To provide a comprehensive overview of Poland's pharmaceutical pricing and reimbursement landscape.
  • To detail the roles of key regulatory bodies in drug evaluation and price negotiation.
  • To outline the requirements and processes for drug reimbursement in Poland.

Main Methods:

  • Review of Poland's healthcare system structure and regulatory framework.
  • Analysis of the drug evaluation process by the Polish Agency for Health Technology Assessment and Tariff System.
  • Examination of pricing and reimbursement negotiation mechanisms involving the Economic Commission.

Main Results:

  • A positive list of reimbursed drugs is updated bimonthly, with reimbursement levels of 100%, 70%, 50%, and lump sum.
  • Reimbursement decisions are time-limited, with initial periods of 2 years, followed by 3 and 5 years.
  • Poland lacks specific provisions for orphan drugs and mandatory generic substitution, with limited real-world data access.

Conclusions:

  • The Polish pharmaceutical reimbursement system involves rigorous evaluation and negotiation processes.
  • Despite efforts to improve access, significant patient co-payments persist.
  • Further policy development may be needed to address orphan drugs and enhance data availability.